Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

RTTNews | 495日前

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

RTTNews | 603日前

Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) and gene editing company CRISPR Therapeutics, Inc. (CRSP) announced Monday that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).

RTTNews | 866日前

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | 1131日前

Canadian Dollar Falls Against Most Majors

The Canadian dollar dropped against its most major counterparts in the New York session on Friday.

RTTNews | 19時41分前

Canadian Market Modestly Higher; Technology Stocks Among Notable Gainers

The Canadian market is up in positive territory Friday afternoon with investors largely reacting to quarterly earnings announcements, and the nation's jobs data, in addition to weighing the impact of tariffs on global economic growth.

RTTNews | 22時3分前

Swiss Market Ends Marginally Up

The Switzerland market ended marginally up on Friday despite exhibiting weakness for much of the time past noon. Investors continued to react to earnings and assess the economic impact of reciprocal tariffs, and stayed largely cautious with their moves. A report showing a drop in Swiss consumer confidence in the month of July hurt sentiment.

RTTNews | 22時38分前

Major European Markets Close On Mixed Note

Major European markets turned in a mixed performance on Friday with investors largely staying cautious, assessing the impact of tariffs on global economic growth, and continuing to digest corporate earnings announcements and other data.

RTTNews | 23時2分前

EURUSD	1.16406	GBPUSD	1.34456	AUDUSD	0.65189
USDJPY	147.742	USDCAD	1.37555	USDCHF	0.80829

Advertisement

Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash